Where are we positioned10 Jun 2026 13:08
1, Scancell can't of received any offers for the company at this point otherwise shareholders would have to be notified.
2, it's quite possible an offer has been made for glymab therapeutics, still in discussion.
3, licencing agreements, but will probably need massive upfront payments. Need to keep the lights on + phase 3 registration trial + pay CLN's that are due next year.
4, Institutional investors sounded out for a placing big enough to take us to 🤞commerciality.
5, There is probably many more routes but who knows.
I just hope whatever they are negotiating is in the best interests of Shareholders now and not 3,4,5 years down the line.
GLA